When every day of delay costs a patient — and a program — 3H closes the gap.
Japan's patient recruitment environment is unlike any other market. Language, trust, regulation, and geography converge to slow even the best-designed trials. The 3H framework was built to solve exactly this.
The 3H Methodology
Patient recruitment in Japan demands more than a translated protocol. It requires deep cultural fluency, proprietary digital infrastructure, and a speed-first operating philosophy. That is what 3H delivers.
High-Touch
Japan's patients and physicians operate within a relationship-first healthcare culture. Trust is not a soft benefit — it is the enrollment prerequisite.
High-Tech
Proprietary digital infrastructure spanning Japan's most trusted clinical trial platforms gives 3H unrivalled reach and data precision.
High-Speed
Enrollment timelines compress when every asset — sites, patients, compliance, and technology — is pre-aligned and activation-ready.
Why Japan recruitment fails without local expertise
Language & Communication Barriers
Global trial materials rarely translate directly into Japanese healthcare communication norms. A protocol that reads clearly in English can feel inaccessible or impersonal to Japanese patients and sites.
Patient Trust & Informed Consent Culture
Japanese patients historically approach clinical trial participation with greater caution. Building awareness and confidence requires sustained, community-rooted engagement — not broad-reach advertising.
Regulatory & Ethics Review Complexity
Navigating Japan's PMDA requirements, IRB structures, and local compliance expectations simultaneously demands specialists. Delays here compound across every downstream activity.
Site Activation Delays
Japanese academic medical centres operate with longer internal decision cycles. Without proactive site relationships and pre-activation protocols, first-patient-in timelines stretch by months.
The bridge between global strategy and local reality
3H MediSolution operates Japan's most comprehensive patient engagement ecosystem — built over two decades within the Japanese healthcare environment. We are not a global CRO applying a regional lens. We are a Japan-native organisation with global connectivity.
Our three proprietary platforms — Oncolo.jp, RareS., and Seikatsu Kojo Web — are trusted by patients, physicians, and advocacy communities. When a sponsor partners with 3H, they gain direct access to the relationships those platforms have spent years building.
- ✓Reach into 1M+ pre-registered Japanese clinical trial participants across therapeutic areas
- ✓Proprietary rare disease and oncology patient networks unavailable through standard CRO channels
- ✓End-to-end Japanese regulatory navigation from feasibility through approval support
- ✓Pre-activated investigator site networks for faster protocol startup
- ✓Real-time enrollment intelligence drawn from live patient registry data
- ✓Bilingual trial communication infrastructure for global sponsor teams
Our recruitment approach
Japan's largest clinical trial volunteer database
3H Group runs "Seikatsu-Kojo WEB", storing disease, medication, and blood type data for over 1,100,000 members. This enables pinpoint identification of highly-suited candidates with extremely high consent rates.
Patient-centred advertisement strategies
We handle all advertising types — newspaper, TV, radio, magazines, web ads, in-transport advertising, pharmacies, post offices, and clinics. We create highly-effective advertisements using unique patient insight techniques within GCP and Pharmaceutical Affairs Law.
Reaching targets beyond web advertising
For hard-to-reach groups such as senior patients, we employ direct recruitment through offline events. We have done bone density scanning for osteoporosis protocols in shopping malls — providing face-to-face interaction for greater security and higher engagement.
Trial branding for smooth trials
We create a precise patient profile for each protocol and develop a clear, patient-centric concept including logo, copy, and messaging. Our tools strengthen the trial impression and simplify the explanation process for physicians and CRCs.
Effectively approaching potential patients
For trials demanding large case numbers, we run "disease awareness" campaigns. With 500+ trials per year, we handle everything from patient analysis to planning, writing, tool creation, and contact centre duties — reducing both manpower and costs.
Oncology
For Medical Affairs and Clinical Operations teams running oncology programs, enrollment gaps in Japan are not a planning inconvenience — they are a competitive and ethical liability. 3H exists to close them.
The oncology enrollment challenge in Japan
Biomarker & Genomic Testing Gaps
Precision oncology trials require pre-screened, biomarker-confirmed patients. Access to Japan's cancer genomics network and companion diagnostic infrastructure is non-trivial without local expertise.
Oncologist Referral Dynamics
Japanese oncologists are the primary gatekeepers to trial participation. Patient self-referral is rare. Trial promotion must run parallel to physician engagement.
Patient Anxiety & Information Asymmetry
Cancer patients in Japan face significant information scarcity about clinical trials as a treatment option. Community-level education is a prerequisite to informed, willing enrollment.
Enrollment Quota Pressure
Global sponsors often set Japan enrollment targets calibrated to ex-Japan market dynamics. Unrealistic quotas unsupported by local infrastructure create site burden and investigator attrition.
The 3H Oncology Enrollment Pathway
Feasibility & Site Intelligence
Live patient registry data from Oncolo and Seikatsu Kojo Web drives rapid feasibility assessments and identifies activation-ready sites.
Physician Network Activation
Our Medical Affairs team engages oncologists and haematologists across Japan's designated cancer care hospital network.
Patient Community Engagement
Disease-specific content campaigns on Oncolo create a continuous pipeline of informed, interested patients.
Screening Support & Navigation
Japanese-speaking patient navigators support pre-screening, eligibility confirmation, and logistics.
Enrollment Monitoring
Real-time dashboards give sponsor teams visibility into Japan-specific enrollment metrics and bottlenecks.
Continuous Optimisation
We refine outreach, site performance, and referral flows before delays become timeline threats.
Rare Disease
Rare disease trials demand a fundamentally different recruitment philosophy. When your eligible population numbers in the hundreds — or fewer — across Japan, standard recruitment methodology fails. 3H was built for exactly this challenge.
Why rare disease recruitment in Japan requires a network, not a campaign
Small n-Numbers & Statistical Power Pressure
With eligible populations sometimes numbering in the dozens across all of Japan, every single patient matters.
Geographic Dispersion Across Prefectures
Rare disease patients are distributed across Japan's 47 prefectures, often distant from major academic centres. Site selection that ignores geography creates access barriers.
Diagnostic Odyssey & Misdiagnosis Burden
Many rare disease patients in Japan have experienced years of misdiagnosis. Reaching them requires proactive registry-level engagement, not passive trial listing.
Genetic & Biomarker Pre-Screening Requirements
Genetically-defined rare diseases require coordination between patient identification, confirmatory testing, and site readiness.
The 3H Rare Disease Enrollment Pathway
Registry-Based Patient Identification
We query RareS., advocacy communities, and national intractable disease registries to build an eligible patient landscape.
Advocacy Group Engagement
Our team establishes trust-based relationships with rare disease advocacy communities and patient groups.
Specialist Physician Network Activation
We engage rare disease specialists, university hospital departments, and designated centres across Japan.
Testing Coordination
For genetically-defined conditions, we pre-arrange confirmatory testing pathways to shorten time to eligibility confirmation.
Site Readiness & Navigation
Remote support, travel coordination, and patient navigation reduce access barriers for geographically dispersed patients.
Feasibility Grounded in Reality
We use live registry data and direct community engagement to calibrate realistic Japan recruitment targets.
Why retention matters
Patient drop-out is one of the biggest challenges in clinical trials — especially for long-term studies. 3H Medi Solution implements comprehensive support measures to ensure that trial participants stay engaged, remember their hospital visits, and manage their medication properly throughout the entire trial.
Personalised pill cases and medication reminders to help patients manage their investigational drug schedules correctly.
Custom appointment memos and calendar tools marked with hospital visit dates to reduce missed visits.
Branded trial amenities such as pens, bags, and patient kits to maintain engagement and connection with the study.
Continuous touchpoints with enrolled patients to ensure they remain informed, motivated, and committed throughout the trial duration.
Proactive identification of at-risk patients combined with targeted interventions to reduce withdrawal rates across all study phases.
Specialist support structures for extended trials where maintaining participant commitment over months or years is critical to study success.